Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

FDA opts for four-letter suffix to distinguish biologics and biosimilars

The US FDA has published long-awaited guidelines on the non-proprietary naming of biological products, but biosimilar makers say adding a random four-letter suffix could needlessly complicate the prescribing system.

Turns out Edwin Starr was wrong - Veterans suited to biopharma says Texas A&M

Army training is good for a biopharma career according to the US National Center for Therapeutics Manufacturing, which is seeking former military personnel interested in learning about bioprocessing.

Shire to use new suppliers to up production of HAE drug filtered from US plasma

Shire will use contractors to increase production of Cinryze, the half billion dollar-a-year Hereditary Angioedema (HAE) drug it bought with ViroPharma in 2014.   

Immatics GmbH founds $60m US T-cell spin-out

German biotech Immatics and the University of Texas have spent $60m on spin-out Immatics US to specialise in adoptive cellular therapies (ACT) for cancer.

Hepalink adding biologics CDMO Cytovance in $200m acquisition

API supplier Hepalink will buy Cytovance for $206m (€183m) in a deal the biologics CDMO says will help expedite its expansion plans.

Biosimilars to have low impact on US employer cost savings, says report

A study commissioned and funded by reference biologic maker AbbVie has found biosimilars will have a smaller cost-saving impact on the US market than previously believed.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...